Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
21 sept. 2021 07h00 HE
|
Lyra Therapeutics
LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis...
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
20 sept. 2021 07h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer
13 sept. 2021 07h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
09 sept. 2021 16h05 HE
|
Lyra Therapeutics
Results demonstrate XTreo™ technology platform provides targeted and sustained dosing of anti-inflammatory medication Outcomes supported advancing into clinical development for LYRA’s first...
Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 07h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31
17 août 2021 07h35 HE
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments
09 août 2021 16h05 HE
|
Lyra Therapeutics
- Successful EOP2 FDA meeting for LYR-210 in CRS; Phase 3 program on track to begin around year-end 2021 - - Licensing agreement with LianBio for LYR-210 in Greater China and other Asian markets - ...
Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9
26 juil. 2021 16h05 HE
|
Lyra Therapeutics
WATERTOWN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference
12 juil. 2021 07h00 HE
|
Lyra Therapeutics
WATERTOWN, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis
30 juin 2021 07h00 HE
|
Lyra Therapeutics
-- Results Support 505(b)(2) NDA Pathway for LYR-210 -- First U.S. Study of LYR-210 Enrolled Rapidly WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA),...